Core Insights - Abolis Biotechnologies has formed a strategic partnership with EUROAPI to develop microbial strains for synthesizing key intermediates and 20 active pharmaceutical ingredients, particularly corticosteroids [1] Company Developments - The partnership aims to leverage Abolis Biotechnologies' expertise in industrial solutions using microorganisms alongside EUROAPI's position as a leading producer of active pharmaceutical ingredients [1] Industry Impact - This collaboration is expected to enhance the production capabilities of key pharmaceutical ingredients, potentially impacting the supply chain and availability of corticosteroid-related products in the market [1]